 |
|
Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART
Richard E. Nettles, MD;
Tara L. Kieffer, PhD;
Patty Kwon, BA;
Daphne Monie, PhD;
Yefei Han, BS;
Teresa Parsons, PhD;
Joseph Cofrancesco, Jr, MD;
Joel E. Gallant, MD, MPH;
Thomas C. Quinn, MD;
Brooks Jackson, MD;
Charles Flexner, MD;
Kathryn Carson, ScM;
Stuart Ray, MD;
Deborah Persaud, MD;
Robert F. Siliciano, MD, PhD
JAMA. 2005;293:817-829.
Context Many patients infected with human immunodeficiency virus type 1 (HIV-1) and receiving highly active antiretroviral therapy experience intermittent episodes of detectable viremia ("blips"), which may raise concerns about drug resistance, lead to costly repeat measurements of viral RNA, and sometimes trigger alterations in therapy.
Objective To test the hypothesis that blips represent random biological and statistical variation around mean steady-state HIV-1 RNA levels slightly below 50 copies/mL rather than biologically significant elevations in viremia.
Design, Setting, and Patients Between June 19, 2003, and February 9, 2004, patients receiving therapy underwent intensive sampling (every 2-3 days) over 3 to 4 months to define the frequency, magnitude, and duration of blips and their association with drug levels and other clinical variables. Blips were defined as HIV-1 RNA measurements greater than or equal to 50 copies/mL preceded and followed by measurements less than 50 copies/mL without a change in treatment. To determine whether blips result from or lead to drug resistance, an ultrasensitive genotyping assay was used to detect drug resistance mutations before, during, and after blips. Patients were 10 HIV-1–infected asymptomatic adults recruited by clinicians and followed up in the Moore Clinic at the Johns Hopkins Hospital. Patients had suppression of viremia to below 50 copies/mL while receiving a stable antiretroviral regimen for 6 months or longer.
Main Outcome Measures At each time point, plasma HIV-1 RNA levels were measured in 2 independent laboratories and drug resistance mutations were analyzed by clonal sequencing.
Results With the intensive sampling, blips were detected in 9 of 10 patients. Statistical analysis was consistent with random assay variation around a mean viral load below 50 copies/mL. Blips were not concordant on independent testing and had a short duration (median, <3 days) and low magnitude (median, 79 copies/mL). Blip frequency was not associated with demographic, clinical, or treatment variables. Blips did not occur in relation to illness, vaccination, or directly measured antiretroviral drug concentrations. Blips were marginally associated (P = .08) with reported episodes of nonadherence. Most importantly, in approximately 1000 independent clones sequenced for both protease and reverse transcriptase, no new resistance mutations were seen before, during, or shortly after blips.
Conclusion Most blips in this population appear to represent random biological and statistical variation around mean HIV-1 levels below 50 copies/mL rather than clinically significant elevations in viremia.
Author Affiliations: Departments of Medicine (Drs Nettles, Kieffer, Monie, Parsons, Cofrancesco, Gallant, Quinn, Flexner, Ray, and Siliciano and Mss Kwon and Han), Pathology (Dr Jackson), and Pediatrics (Dr Persaud), Johns Hopkins University School of Medicine, Baltimore, Md; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md (Dr Quinn); Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (Ms Carson); and Howard Hughes Medical Institute, Baltimore (Dr Siliciano). Dr Kieffer is now employed at Vertex Pharmaceuticals, Cambridge, Mass. Dr Monie is now employed at Decision Resources Inc, Waltham, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy
Shiu et al.
J. Virol. 2009;83:9731-9742.
ABSTRACT
| FULL TEXT
A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy
Dinoso et al.
J. Virol. 2009;83:9247-9257.
ABSTRACT
| FULL TEXT
Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy
Brennan et al.
J. Virol. 2009;83:8470-8481.
ABSTRACT
| FULL TEXT
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
Dinoso et al.
Proc. Natl. Acad. Sci. USA 2009;106:9403-9408.
ABSTRACT
| FULL TEXT
Cost-effectiveness of HIV Monitoring Strategies in Resource-Limited Settings: A Southern African Analysis
Bendavid et al.
Arch Intern Med 2008;168:1910-1918.
ABSTRACT
| FULL TEXT
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle
Proc. Natl. Acad. Sci. USA 2008;105:4832-4837.
Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors
Gandhi et al.
J. Virol. 2008;82:3125-3130.
ABSTRACT
| FULL TEXT
Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome
Garcia-Gasco et al.
J Antimicrob Chemother 2008;61:699-704.
ABSTRACT
| FULL TEXT
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel
Hammer et al.
JAMA 2006;296:827-843.
ABSTRACT
| FULL TEXT
Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells.
Bailey et al.
J. Virol. 2006;80:6441-6457.
ABSTRACT
| FULL TEXT
Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.
Bailey et al.
J. Virol. 2006;80:4758-4770.
ABSTRACT
| FULL TEXT
HIV-1 viral load blips are of limited clinical significance
Lee et al.
J Antimicrob Chemother 2006;57:803-805.
ABSTRACT
| FULL TEXT
Clinical practice. Management of newly diagnosed HIV infection.
Hammer
NEJM 2005;353:1702-1710.
FULL TEXT
Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus
Tobin et al.
J. Virol. 2005;79:9625-9634.
ABSTRACT
| FULL TEXT
Fears of HIV resistance prove unfounded
British Journal of Infection Control 2005;6:10-10.
Viral "Blips": Don't Worry, Be Happy
AIDS Clin Care 2005;2005:3-3.
FULL TEXT
How Worrisome Is Intermittent HIV Viremia?
JWatch Infect. Diseases 2005;2005:3-3.
FULL TEXT
Medical Applications of Biotechnology
Fontanarosa and DeAngelis
JAMA 2005;293:866-867.
FULL TEXT
|
